



OLYMPUS



Olympus Corporation

Company Presentation

April 2026 Ver. 1

Disclaimer:

- Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.
- Some of the products and/or technology shown herein are future technology concepts that are under development and are not presently available in all countries, including not being available in the United States. There is no time period established as to when or if these products and/or technologies will be available in such markets, including the United States. The safety and effectiveness of these products and technologies and/or the use of these products and technologies have not yet been established in the United States market.
- The content of this presentation may contain off-label information and is intended only for the discussion of the potential future use of new technologies and products. Specifications, design, and accessories are subject to change without any notice or obligation on the part of the manufacturer. There is no time period established as to when or if these products and/or technologies will be available in the United States or other countries.

Content

1. As a Globally Leading MedTech Company
2. Our Business Fields
3. Company Strategy
4. For a Sustainable Society
5. Company Information
6. Appendix: Olympus History

As a Globally
Leading MedTech
Company

01



Corporate Philosophy

Our Purpose

Making people's lives healthier, safer and more fulfilling


Our Core Values

				
PATIENT FOCUS	INTEGRITY	INNOVATION	IMPACT	EMPATHY
We put patients at the heart of everything.	We do the right thing.	We look for new ways to make things better.	We take accountability and get things done.	We care for one another and work together.

Since developing the world's first practical gastroscope in 1950, Olympus has worked alongside healthcare professionals to contribute to the evolution of endoscopy.

To embody Our Purpose of “Making people's lives healthier, safer and more fulfilling,” we are committed to elevating the standard of care to improve outcomes.

Patient Focus, Integrity, Innovation, Impact, and Empathy: our redefined set of five core values. We continuously develop them as a global MedTech company, prioritizing patient safety and quality.


A couple stands on a grassy mountain peak, looking out over a vast mountain range under a sky filled with large, white clouds. The scene is captured in a cinematic style with warm lighting, suggesting a sunrise or sunset. The couple is seen from behind, emphasizing their shared experience of the view.

True to Life

"True to Life" is our global brand message that expresses Olympus's commitment to Our Purpose.

At Olympus, we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.

Olympus Locations



29,297

Employees Worldwide*

40

Countries or Regions*

* As of March 2025

Our Contribution to Patient Care

49M

Colonoscopies Performed Worldwide Annually

*Numbers of US, Germany, France, UK, Italy, Spain, Japan, Canada, Poland, South Korea, Australia, India, Russia (as of 2022); China (as of 2019 including annual averages from 2019 to 2022 forecasts)

Source: Based on the Company's research, as of March 2025

TOP 100

Global Innovator

Since 2012 to 2020, and in 2022 and 2023, Olympus has been awarded as one of the top 100 most innovative companies in the world.

<https://clarivate.com/top-100-innovators/>

100

Diseases or Conditions Treated

At Olympus we have versatile medical devices with the ability to treat approximately 100* diseases or conditions

Source: Based on the Company's research, as of March 2025

297

Awards

Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*

*As of March 2025

TOP 3

Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach - Three cancers from the top 5* highest incidence of cancers

*Top 3 highest incidence of cancers excluding breast and prostate cancer Source: GLOBOCAN 2022 <https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf>

15,000

Patents

Across our product portfolio*

*As of March 2025

Our Business Fields

02



Revenue by Business Divisions/Region





Source: Financial Data for FY2025

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).

*Due to rounding, the total may not add up to 100%

Revenue and Operating Profit



*Due to rounding, the total may not add up to 100%

Source: Financial Data for FY2025

Gastrointestinal Solutions Division

Gastrointestinal Endoscopy System



Video endoscopy system



Ultrasound system

GI Endotherapy



CRC devices



HPB devices




Hemostasis

Endoscopic Solutions Ecosystem (Digital Healthcare Solutions)



Intelligent ecosystem operating software platform



AI insights and computer-aided detection/diagnosis

Reprocessing



Endoscope reprocessor



Chemicals, accessories, and peripherals

Medical Services



Repair center

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS). Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions. The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development – These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Surgical and Interventional Solutions Division

Respiratory



Bronchoscopy Systems

Bronchoscopic Devices



Lung Cancer diagnosis/staging



COPD
(Chronic Obstructive Pulmonary Disease)

Urology



Visualization



Stone Management



BPH
(Benign Prostatic Hyperplasia)



BPH + Bladder Cancer

Surgical (Surgical Endoscopy, Surgical Devices, Ear, Nose, and Throat)



Surgical Endoscopy Systems



Advanced Energy Devices



Surgical Microscope



Integrated Procedure Room Solutions



Rhino-Laryngo Videoscope Solutions

Note: We re-aligned our divisional structure from April 2025. The Endoscopic Solutions Division (ESD) and the Therapeutic Solutions Division (TSD) transitioned into the new divisions of the Gastrointestinal Solutions Division (GIS) and the Surgical & Interventional Solutions Division (SIS).

Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

The Digital Healthcare Solution Products and Technology shown on this slide are Concepts and Solutions Under Development - These products have not been submitted to the FDA and are Not available for Sale in the U.S.A.

Corporate Strategy

03



Global Trends Show Increasing Demand for Endoscopy Procedures, Underpinned by Macroeconomic Factors and the Need for Better Care


Global demand drives 5% annual growth of endoscopy-enabled care¹

- Aging populations (>40% of the global population over 60)
- Growing prevalence in GI, urological, and lung cancers
- Broadening access to care

Opportunity for further growth

- Accelerating access in underserved geographies
- Scaling established procedures like ERCP and ESD
- Expanding into adjacent disease areas and procedures that today rely on more invasive methods

1. Market value growth base on AcuityMD, Ministries of Health, IQVIA FlexView MedTech, Olympus China primary market research 2. Based on Olympus' market insights derived from IQVIA FlexView MedTech
3. Assumes global per capita utilization matches US/EU/Japan/China levels



A New Vision for Endoscopy-Enabled Care Is Needed to Deliver Against Healthcare Needs and Opportunities



Patients

Endoscopy that's advanced and less invasive brings clarity and comfort.

- New Tech can enhance early detection & accuracy, may reduce unnecessary biopsies
- Same-day results ease anxiety
- Less invasive care supports faster recovery

Clinicians

Endoscopy made safer, smarter, and more consistent

- Tech can lighten manual and cognitive load
- Automation can free time for clinical decisions and patient communication
- Complex procedures can become consistent and reproducible
- Nurses manage data for continuity of care

Administrators

Advanced technology can drive efficiency and lowers costs

- Predictive maintenance and smart fleet management can increase uptime
- Single-use and modular tools can simplify logistics
- Streamlined operations can cut costs and help support compliance with standards

Olympus Is Positioned to Deliver on That Future



A Backbone of Scalable Endoscopy

Large installed base of interoperable towers for scalable, integrated workflows, including service/support and training available to support improved uptime



Advanced Endoscopes and Therapeutic Devices

Broad portfolio of scopes and therapeutic devices to detect, diagnose, and treat disease across major specialties and care settings



Smart Technologies Driving the Future

AI, robotics, and workflow management to optimize procedures and outcomes

Olympus Is Accelerating Investments in the Endosuite¹ of the Future



Integrate AI into the endoscopy ecosystem

OLYSENSE CAD/AI launched commercially (US and selected EU). By FY28 and 31, aiming to integrate OLYSENSE in 5% and 25% of our global installed base, respectively.



Build robotic endoluminal solutions

Swan EndoSurgical and other partnerships lay the foundation for establishing new GI care standards, designed to support procedural efficiency and broaden access to advanced therapeutic techniques.



Expand advanced diagnostic and therapeutic portfolio

Develop, partner, and acquire advanced solutions that are designed to detect, diagnose, and treat disease, and equip healthcare professionals to fight disease across our clinical and disease focus areas.

¹ A solution that could extend the reach of endotherapies while improving the patient experience, using artificial intelligence (AI) and other digital tools and technologies.

Note: Products shown may not be available in all regions. As with any medical device, careful consideration should be given to all applicable labeling, including potential risks and benefits associated with the product.

Envisioning the Future of Endoscopy-Enabled Care



Better care

Detect diseases earlier
Same day diagnosis,
staging, and
treatment

Expanding minimally-
invasive therapeutic
options, reducing
reliance on surgery

Enabling more
diseases to be
treated
endoscopically

Driving
efficiencies
through smart
workflows

Powered by an integrated ecosystem

Ecosystem of cloud connected
hardware, devices, software and
services, paired with cutting
edge optics, AI and robotics

Integrated data to
generate individualized
and predictive insights at
the point of care

Where Purpose Meets Performance: Shaping the Future of Endoscopy-Enabled Care

OUR PURPOSE

Making people's lives healthier, safer and more fulfilling

Innovation-Driven Growth

Lead the next wave of innovation & expand to faster-growing segments

- Fortify portfolio through focused investments
- Shape the future of endoscopy through OLYSENSE and robotics
- Enhance performance in China and set direction for emerging markets
- Drive M&A tuck-ins in close adjacencies

OUR STRATEGIC PILLARS

Simplicity

Simplify Olympus to move faster and operate smarter

- Build a lean, division-led operating model and governance at competitive cost base
- Further harmonize end-to-end processes and leverage AI
- Improve innovation model for continuous and accelerated release of new products
- Build resilient, flexible and efficient manufacturing and supply chain

Accountability

Instill a high-performance culture of ownership and execution

- Embrace a patient-first mindset, embedding quality & safety into every step of work
- Deliver ESG commitments
- Establish a global Olympus management system

OUR FINANCIAL ASPIRATIONS FY27-29

Revenue¹

~5 %

Growing at 5% by FY29

Op Margin²

~100 bps

Year-on-year growth from FY26

EPS CAGR²

>10 %

From FY2026


¹ Constant Currency basis ² Adjusted for extraordinary items: Exclude "Other income/expenses, no adjustment will be made for the impact of exchange rate fluctuations, actual exchange rate will be used.

For a Sustainable Society

04



Common Topics in ESG*



Environment

- Climate Change/Carbon Neutrality
- Circular Economy
- GHG Emissions
- Water & waste management



Social

- Human Rights
- Inclusion
- Workplace safety
- Healthcare Access & Outcome



Governance

- Corporate Risk Management
- Management Structure
- Reporting Transparency

*Major examples only / not limited

Sustainability 

ESG six focus areas and materiality topics for contributing to solutions to social issues



Healthcare Access and Outcome

Contribution to health equity and access



Compliance, Product Quality and Safety

Quality and safety in product, service and solution



Responsible Supply Chain

Supply chain risk mitigation and resilience



Healthy Organization

Inclusion



Carbon Neutral Society and Circular Economy

Circularity through product stewardship, carbon emissions (Scope 1, 2 and 3)



Corporate Governance

Corporate governance and reporting transparency

For Sustainable Society – Olympus' Initiative



Healthcare Access and Outcomes

Contributing to improvements in healthcare standards in India by supporting outreach gastrointestinal endoscopic screenings

[Impact Action Stories](#) 



Compliance, Product Quality and Safety

Driving *Elevate*, our holistic remediation and quality transformation program



Responsible Supply Chain

Building a resilient supply chain through data utilization and strengthened supplier partnerships

For Sustainable Society – Olympus' Initiative



Carbon Neutral Society and Circular Economy

Aizu Olympus implements long-term practical measures to reduce greenhouse gas emissions

[Impact Action Stories](#) 



Corporate Governance

Delivering aligned assurance



Supporting Physician Development in Emerging Countries

Supporting the development of physicians, through collaborative efforts involving industry, government and academia

[Supporting Physician Development in Emerging Countries](#) 

Company Information

05



Company Outline

Company Name	Olympus Corporation
Market	Tokyo Stock Exchange, Prime Market (7733)
Established	October 12, 1919
Head Office	2951 Ishikawa-machi, Hachioji-shi, Tokyo 192-8507, Japan
Share Capital	124.643 billion yen (As of March 31, 2025)
Consolidated Revenue	997.3 billion yen (Fiscal year ended March 31, 2025)
Consolidated Headcount	29,297 (As of March 31, 2025)
Corporate Website	https://www.olympus-global.com/



Key Overseas Sites

U.S.A.: Manufacturing sites: 2 sites

Center Valley (HQ)

Brooklyn Park

Product types: Surgical energy devices

Redmond

Product types: Bronchoscopy devices;
Spiration valve system

Westborough (Surgical and Interventional Solutions Business HQ)

Europe: 5 Manufacturing sites

Germany: Hamburg (HQ)

Product types : Surgical rigid speculum

Germany: Berlin

Product types : High frequency generator

Czech Republic: Přerov

Product types: Urological devices

United Kingdom: Plymouth

Product types: Medical related products

United Kingdom: Southend-on-Sea

Product types : Endoscope peripheral
equipment (trolley, insufflator)

Asia: Manufacturing sites: 2 sites

China: Beijing (HQ)

Suzhou


Endoscope assembly

Hong Kong (HQ)

Vietnam

Product types : Treatment
devices

Domestic Sites and Production Sites



Executive Officers



Bob White

Director, Representative Executive Officer, President and Chief Executive Officer



Simone Berger

Executive Officer and Chief Human Resources Officer



Keith Boettiger

Executive Officer and Gastrointestinal Solutions Division Head



John de Csepel

Executive Officer and Chief Medical Officer



Gabriela Kaynor

Executive Officer and Chief Strategy Officer



Seiji Kuramoto

Executive Officer and Surgical and Interventional Solutions Division Head



Syed Naveed

Executive Officer and Chief Technology Officer



Michael Parenti

Executive Officer and Chief Financial Officer



David Shan

Executive Officer and Chief Manufacturing and Supply Officer



Boris Shkolnik

Executive Officer and Chief Quality Officer



Neil Boyden Tanner

Executive Officer and Global General Counsel

Appendix: Olympus History

06



Olympus History



Sales launch of **Asahi** microscope.

1920



Renaming of company to **Olympus Optical Co., Ltd.**

1949



Start up of **Olympus Optical Co.** in Hamburg, Germany, as Olympus' European headquarters.

1964



Collaboration with Winter & Ibe GmbH to produce surgical rigid medical endoscopes, with Olympus supplying the optical systems.

1975

1919

Founding of **Olympus** by Takeshi Yamashita under the company name **Takachiho Seisakusho**; established in Tokyo, Japan, for domestic production of microscopes.



1936

Launch of first Olympus camera, the **Semi-Olympus I**, after development of Zuiko photographic lenses.

1950

Development of world's **first practical** gastrocamera.




1968

Establishment of **Olympus Corporation of America** as a sales subsidiary for microscopes and medical equipment in the United States.



Olympus History



OLYMPUS
